Insmed IncorporatedProfile
|
|
Share Price & Volume
| Previous Close | $143.57 | |
| Open | -1.78% | $141.02 |
| Day Low | -2.56% | $139.89 |
| Day High | +0.47% | $144.24 |
| 52-Week Low | -57.93% | $60.40 |
| 52-Week High | +48.19% | $212.75 |
| Day Volume | 2,486,741 | |
| Average Volume | 2,970,720 | |
| EPS (TTM) | -$6.42 | |
| P/E (TTM) | -21.83x | |
| FWD P/E (NTM) | 16.37x | |
| Next Earnings Date | May 7, 2026 |
| Market Cap | 30,205,287,186 | |
| Shares Outstanding (Millions) | 215,551,896 | |
| Dividend | - | |
| Beta | 1.17 | |
| ROE | -2.49% | |
| ROA | -0.29% |
Analyst Ratings and Price Targets
Current:
$140.13
Average:
$221.47
(+58.05%)
Low:
$162.00
(+15.61%)
High:
$269.00
(+91.96%)
| Mizuho | Maintains | Outperform | $204.00 | +45.58% | Feb 24, 2026 |
| HC Wainwright & Co. | Reiterates | Buy | $230.00 | +64.13% | Feb 23, 2026 |
| Wells Fargo | Maintains | Overweight | $208.00 | +48.43% | Feb 20, 2026 |
| Morgan Stanley | Maintains | Equal-Weight | $162.00 | +15.61% | Jan 30, 2026 |
| Barclays | Initiates Coverage On | Overweight | $231.00 | +64.85% | Jan 28, 2026 |
| Roth Capital | Initiates Coverage On | Buy | $212.00 | +51.29% | Jan 23, 2026 |
| RBC Capital | Maintains | Outperform | $200.00 | +42.72% | Jan 21, 2026 |
| UBS | Maintains | Buy | $215.00 | +53.43% | Jan 6, 2026 |
| TD Cowen | Maintains | Buy | $241.00 | +71.98% | Dec 18, 2025 |
| Goldman Sachs | Maintains | Buy | $225.00 | +60.57% | Dec 18, 2025 |
| HC Wainwright & Co. | Maintains | Buy | $230.00 | +64.13% | Dec 18, 2025 |
| Guggenheim | Maintains | Buy | $221.00 | +57.71% | Dec 18, 2025 |
| RBC Capital | Maintains | Outperform | $195.00 | +39.16% | Dec 18, 2025 |
| Wells Fargo | Maintains | Overweight | $234.00 | +66.99% | Dec 16, 2025 |
| Cantor Fitzgerald | Maintains | Overweight | $230.00 | +64.13% | Dec 16, 2025 |
| Goldman Sachs | Maintains | Buy | $258.00 | +84.11% | Dec 15, 2025 |
| TD Cowen | Maintains | Buy | $269.00 | +91.96% | Dec 11, 2025 |
Headquarters
Bridgewater, NJ, USA
Industry
# of Employees
1,271